Medical Condition News

RSS

NIDA resource to guide individuals and families struggling with addiction

A new resource, Seeking Drug Abuse Treatment: Know What to Ask, will help individuals and families struggling with addiction ask the right questions before choosing a drug treatment program. It was developed by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, and is available to the public free online or in hard copy through NIDA's DrugPubs service.

18 Jan 2012

Inmates with severe mental illnesses alone have lower rates of recidivism

People with mental illness have gotten a bad rap in past research studies, being labeled the group of people with the highest return rates to prison. But a researcher from the Mandel School of Applied Social Sciences at Case Western Reserve University counters those findings in a new study-demonstrating that inmates with severe mental illnesses alone actually have lower rates of recidivism than those with substance abuse issues or no mental or substance abuse issues.

18 Jan 2012

New motion capture technology offers fresh insights into tennis injuries

A new approach to motion capture technology is offering fresh insights into tennis injuries - and orthopedic injuries in general.

18 Jan 2012

New computational modeling methods book for ophthalmologists

Dr. Sumeet Dua, the Upchurch Endowed Professor of Computer Science and coordinator of information technology research at Louisiana Tech University, has co-edited a new book on computational modeling methods that can help ophthalmologists develop innovative computer systems to provide critical support and better care options for patients.

18 Jan 2012

Study finds Medicare doesn't pay adequately for clot-busting stroke treatment

Treating stroke patients with clot-busting drugs costs U.S. hospitals substantially more than Medicare pays, a new study finds.

18 Jan 2012

Innovative computer algorithm identifies clinically prognostic marker for cancer

Researchers at the Stanford University School of Medicine have used an innovative mathematical technique to find markers that effectively predict how deadly a cancer will be. The discovery, which in this case concerned bladder cancer, could lead to faster, less expensive and more accurate analysis of cancer risk and better treatment of the disease.

18 Jan 2012

New path for individually tailored cancer therapy

The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy.

18 Jan 2012

Research reports on effectiveness of Scriptaid in breast cancer cell lines

Although endocrine therapy for breast cancer has shown excellent results in controlling the disease, responsiveness to the therapy depends on whether or not there is expression of estrogen receptors in breast cancer cells. Research from the Sbarro Institute for Cancer Research and Molecular Medicine, a nonprofit cancer, cardiovascular and diabetes research center located in Philadelphia, PA, reports on the effectiveness of a new molecule, Scriptaid, that restores receptivity to endocrine therapy in breast cancer cell lines that had tested negative for the expression of estrogen receptors.

18 Jan 2012

Study compares adoptive T-cell therapy with drug-based cancer treatment

In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments.

18 Jan 2012

Teenagers more susceptible to addiction and depression

Teenagers are more susceptible to developing disorders like addiction and depression, according to a paper published by Pitt researchers Jan. 16 in the Proceedings of the National Academy of Sciences.

18 Jan 2012

Scientists identify hepsin protein's role in breast cancer

Cancers rarely are deadly unless they evolve the ability to grow beyond the tissues in which they first arise. Normally, cells -- even early-stage tumor cells -- are tethered to scaffolding that helps to restrain any destructive tendencies. But scientists from the University of Helsinki, Finland, and from UCSF have identified a cleaver-wielding protein that frees some tumor cells, allowing them to further misbehave.

18 Jan 2012

Combination of tenotomy and PRP injections can treat tendon disorders

Many athletes know the frustration of being sidelined by tendon disorders, like Achilles tendinitis and tennis elbow. In recent years, doctors have begun treating overused tendons with regenerative therapies that jump-start the body's own healing process. One technique, a tenotomy, uses repeated needlesticks to break up scar tissue in the tendon, prompting the body's own cells to begin the rebuilding process.

18 Jan 2012

Researchers develop simple process for synthesis of artemisinin

The most effective anti-malaria drug can now be produced inexpensively and in large quantities. This means that it will be possible to provide medication for the 225 million malaria patients in developing countries at an affordable price. Researchers at the Max Planck Institute of Colloids and Interfaces in Potsdam and the Freie Universit-t Berlin have developed a very simple process for the synthesis of artemisinin, the active ingredient that pharmaceutical companies could only obtain from plants up to now.

18 Jan 2012

Voraxaze receives FDA approval for treatment of toxic methotrexate levels

The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure.

18 Jan 2012

Novelos initiates enrollment in HOT Phase 1b trial for advanced solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has enrolled the first patient in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound (131)I-CLR1404 (HOT) in cancer patients with advanced solid tumors.

18 Jan 2012

'Pro-survival' protein inhibitors may improve outlook for AML patients

Melbourne researchers have discovered that acute myeloid leukaemia (AML), an aggressive blood cancer with poor prognosis, may be susceptible to medications that target a protein called Mcl-1.

18 Jan 2012

Bionime, GE enter licensing agreement to provide diabetes solutions

GE today announced it has entered into a new worldwide licensing agreement with Bionime, a global leader in biotechnology medical testing, to provide new GE-branded solutions for the diabetes market.

18 Jan 2012

Scientists identify compound that can help repair toxic RNA defect

Scientists from the Florida campus of The Scripps Research Institute have identified a compound that can help repair a specific type of defect in RNA, a type of genetic material.

18 Jan 2012

Vitamin D supplements can fight against age-related macular degeneration

Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have found that vitamin D reduces the effects of ageing in mouse eyes and improves the vision of older mice significantly. The researchers hope that this might mean that vitamin D supplements could provide a simple and effective way to combat age-related eye diseases, such as macular degeneration (AMD), in people.

17 Jan 2012

Regorafenib lengthens lives of patients with metastatic colorectal cancer

An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.

17 Jan 2012